About Technology Issues FAQ

Links

Official Page

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.